Chem Company Seeks Bulk Schedule I Drug Making License
Published Date: 9/24/2026
Notice
Summary
Cayman Chemical Company wants to become an official bulk maker of some powerful controlled substances, mostly in Schedule I. This means they’ll be able to produce these drugs in large amounts for research or medical use. If you have thoughts or objections, you’ve got until November 23, 2026, to speak up online—no fees or money changes yet, just a chance to weigh in!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Application to bulk manufacture many controlled substances
On August 5, 2026, Cayman Chemical Company (1180 East Ellsworth Road, Ann Arbor, Michigan) applied to be registered to bulk manufacture a long list of controlled substances in Schedules I and II. The company says it plans to bulk manufacture these substances for forensic purposes, to produce analytical reference standards for research, and as Active Pharmaceutical Ingredients for Phase 1 clinical trials.
Public comment and hearing deadline
The notice gives registered bulk manufacturers and applicants until November 23, 2026 to submit electronic comments or to file a written request for a hearing about Cayman Chemical Company’s application. Comments must be submitted through https://www.regulations.gov and you will receive a Comment Tracking Number upon submission.
Synthetic marijuana / THC production limited
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Cayman Chemical Company states it plans to bulk manufacture these drugs as synthetic products. The notice says no other activities for these specific drug codes are authorized for this registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2026-19541, Bulk Manufacturer of Controlled Substances Application: Eli-Elsohly Laboratories
Eli-Elsohly Laboratories wants to become a big-time maker of certain controlled substances like marijuana extracts and some strong medicines. People and companies involved with these drugs can share their thoughts or ask for a hearing by November 23, 2026. This move could impact drug supply and research, but no costs or changes to users are expected right now.
Next: 2026-19543, Certain Boiler Protection for Absorption Refrigeration Systems and Components Thereof; Notice of the Commission's Final Determination Finding a Violation of Section 337; Issuance of a General Exclusion Order and Cease and Desist Orders; Termination of the Investigation
The U.S. International Trade Commission found that some imported boiler protection parts for absorption refrigeration systems break patent rules. They’re banning these products from entering the U.S. and ordering the companies involved to stop selling them. This protects American innovators and could shake up the market starting now.